It is our goal to provide innovative treatment options for diseases with high unmet medical need.
By fostering collaborations with excellent academic groups and start-ups we aim to translate ideas from basic research into novel drugs.
In order to further pool expertise and to join forces for mutual benefit, Bayer HealthCare has initiated the Grants4Targets program to support collaborative research projects on novel molecular targets in the fields of Oncology, Gynecology, Cardiology, Hematology, and Ophthalmology. To promote the validation of novel target and biomarker ideas, we have set up a grant scheme and provide our expertise in drug discovery. We look forward to hearing about your innovative ideas!
What targets are we looking for in G4T?
According to our definition a “druggable” target is a nucleic acid or a protein (e.g. an enzyme, a receptor) whose activity can be modified by external drug stimuli. Drugs can be low molecular weight compounds or biologics such as antibodies or recombinant proteins. We are looking for novel molecular targets and disease related biomarkers in the fields of:
||Focus on oncogenic signaling
||Focus on novel treatment options for endometriosis (incl. adenomyosis uteri /endometriosis interna), uterine fibroids (uterine leiomyoma) and polycystic ovary syndrome (PCOS)
||Focus on novel approaches to the care of chronic and/or acute pulmonary hypertension & adjacent lung indications, atrial fibrillation, heart failure, acute coronary syndrome, ischemic stroke, peripheral arterial occlusive disease, acute lung injury/adult respiratory distress syndrome, cardiorenal syndrome and including kidney and lung diseases.
||Focus on novel, innovative targets for hemophilia.
How can I apply?
Target ideas can be submitted via our website www.grants4targets.bayer.com.
In addition to the submission tool, further detailed information about this program can be found at this website. After a comprehensive internal review process by Bayer HealthCare scientists, feedback will be provided within approximately eight weeks after submission deadline. To foster close collaborations Bayer HealthCare scientists are nominated as project partners to bring in their know-how on target validation and to provide tools such as compounds or models depending on the project.
What types of grants are we offering?
Support Grants €5,000-10,000
To further advance research on targets that are at a very early stage of discovery; fixed grant approval letter; IP rights remain with the applicant.
Focus Grants €10,000-125,000
For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug discovery process; fixed grant approval letter; IP rights remain with the applicant.
- Grant types do not need to be selected by the grant applicant. The decision on grant allocation is made at the sole and absolute discretion of Bayer HealthCare.
- Successful projects supported by a grant may lead to further collaborations.
- In addition to financial grants we offer our expertise, tools and/or technologies such as antibodies, tool compounds, biobank samples.
(External website “Grants4Targets”)